Clinical Trial

A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is the first-in-human Phase I study of SYS6040 for injection, comprising two phases: Dose escalation with backfill (Phase Ia) and cohort expansion (Phase Ib).The planned study population consists of subjects with advanced solid tumors.The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SYS6040 for injection as monotherapy in participants with advanced solid tumors.
Trial Details
NCT Number NCT06970795
Lead Sponsor CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions Small Cell Lung Cancer, Other Advanced Solid Tumors
Enrollment 180 participants
Start Date 2025-04-10
Primary Completion 2027-02-28 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-14